TABLE 2.
Donor, recipient, and intraoperative factors were compared between recipients who developed EAD and those who did not develop EAD separately for the DCD group and DBD group
| Factors | DCD group | DBD group | |||||
|---|---|---|---|---|---|---|---|
| EAD = 0 (N = 30) | EAD = 1 (N = 73) | P | EAD = 0 (N = 573) | EAD = 1 (N = 392) | P | ||
| Recipient factors | |||||||
| BMI | 24.4 (22.1–28.4) | 27.0 (23.3–29.9) | 0.13 | 26.4 (23.7–30.3) | 27.8 (24.7–31.0) | <0.01 | |
| MELD | 16.0 (11.2–25.2) | 18.0 (12.0–27.5) | 0.55 | 18.0 (11.0–24.0) | 15.0 (9.00–24.0) | 0.01 | |
| HCV | 0 | 17 (56.7%) | 45 (61.6%) | 0.8 | 367 (64.0%) | 275 (70.2%) | 0.057 |
| 1 | 13 (43.3%) | 28 (38.4%) | 206 (36.0%) | 117 (29.8%) | |||
| Na-MELD | 21.0 (13.9–27.3) | 20.0 (13.0–31.9) | 0.75 | 21.1 (13.2–28.0) | 19.8 (11.1–28.5) | 0.16 | |
| Donor factors | |||||||
| Age | 40.0 (24.0–49.0) | 39.5 (25.5–55.0) | 0.64 | 49.0 (32.0–61.0) | 53.0 (42.0–63.0) | <0.001 | |
| BMI | 22.9 (21.3–25.6) | 25.3 (22.6–27.6) | 0.03 | 25.8 (8–42) | 26.8 (16–49) | <0.001 | |
| Gender | Female | 9 (30.0%) | 17 (23.3%) | 0.43 | 245 (42.8%) | 144 (36.7%) | 0.02 |
| Male | 20 (66.7%) | 55 (75.3%) | 328 (57.2%) | 245 (62.5%) | |||
| Operative factors | |||||||
| CIT | 301 (276–336) | 342 (298–382) | 0.01 | 430 (344–522) | 452 (358–540) | 0.02 | |
| WIT | 53.5 (41.5–59.5) | 54.0 (45.0–60.5) | 0.6 | 48.0 (41.0–55.0) | 53.0 (44.0–61.2) | <0.001 | |
| EBL | 2.3 (1.5–4.5) | 3.5 (2–5.5) | 0.10 | 2 (1.2–3.5) | 2.5 (1–4.5) | 0.057 | |
| CA_1ha | 0.03 (0.04) | 0.06 (0.06) | 0.06 | 0.03 (0.05) | 0.04 (0.07) | 0.059 | |
| CA_finala | 0.01 (0.03) | 0.03 (0.05) | 0.053 | 0.01 (0.04) | 0.02 (0.05) | 0.12 | |
| Postoperative factors | |||||||
| Cr_2wks | 9 (30.0%) | 39 (53%) | 0.03 | 206 (36.0%) | 187 (48.0%) | <0.001 | |
All the factors presented in Table 1 were analyzed. Above are presented only the factors which reached significance. Data are given as n (%) or median (range) unless otherwise noted.
aData given as mean ± SD.
BMI, body mass index; CA_1h, catecholamine amount at 1 h after the start of the transplant; CA_final, catecholamine administration at the end of the transplant; CIT, cold ischemia time, min; Cr_2 wks, elevated creatinine > 150 μmol/L at 2 wk posttransplantation; DBD, donation after brain death; DCD, donation after circulatory death; EAD, early allograft dysfunction; EBL, estimated blood loss, L; HCV, hepatitis C virus; MELD, model for end-stage liver disease; Na-MELD, sodium MELD; WIT, warm ischemia time of recipient, min.